Niacinamide, an inexpensive form of vitamin B3 sold as an oral supplement and skin-care ingredient, is studied for skin and eye health. Strongest support is fewer new sun-related skin cancers in people who have had several, lasting only during use. Topical support for appearance and acne is moderate. Glaucoma eye protection is unproven; slowing aging is not supported in humans. At studied doses, digestive upset is the main side effect. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT, AST | Within laboratory range, ALT roughly 7–55 U/L | Safety check: a rise prompts dose reduction or stopping |
| Platelet count | 150–450 × 10⁹/L | Safety check in kidney failure: a fall prompts review |
| Serum phosphate | 2.5–4.5 mg/dL | Expected to change in dialysis patients |
| Fasting glucose | 70–99 mg/dL | Safety check: a rise may reflect reduced insulin sensitivity |
| Homocysteine | About 5–15 µmol/L | Expected to change: methyl-group use may raise it |
| Serum creatinine | About 0.6–1.3 mg/dL | Safety check: reduced kidney function raises platelet and accumulation risk |
| New skin cancers and actinic keratoses (dermatologist examination) | No established target; track new-lesion count against the prior year | Expected to change: fewer new lesions indicate response |
| Visual field and OCT (glaucoma) | No established target; track change from own baseline | Expected to change: stability indicates response |
Cadence: Baseline panel before starting; recheck 3 months after starting or any dose increase, then every 6–12 months at doses up to 1 g/day and every 3 months at higher doses. Dialysis patients recheck platelets and phosphate monthly for the first three months. Skin examinations every 3–6 months; glaucoma testing at the usual eye-care interval.